REVIEW

Functional characterization of wild-type and mutated pendrin (SLC26A4), the anion transporter involved in Pendred syndrome

Silvia Dossena¹, Simona Rodighiero², Valeria Vezzoli¹,³, Charity Nofziger¹, Elisabetta Salvioni¹,³, Marta Boccazzi¹,³, Elisabeth Grabmayer¹, Guido Botta³, Giuliano Meyer³, Laura Fugazzola⁴,⁵, Paolo Beck-Peccoz⁴,⁵ and Markus Paulmichl¹

¹Institut of Pharmacology and Toxicology, Paracelsus Medical University, A-5020 Salzburg, Austria
²CIMAINA, ³Department of Biomolecular Sciences and Biotechnology and ⁴Department of Medical Sciences, Università degli Studi di Milano, I-20133 Milan, Italy
⁵Endocrine and Diabetes Unit, Fondazione Policlinico, IRCCS, I-20122 Milan, Italy

(Correspondence should be addressed to M Paulmichl; Email: markus.paulmichl@pmu.ac.at)

Abstract

Pendred syndrome (PS) is the most frequent form of genetically related syndromic hearing loss, and is associated with mutations of pendrin, encoded by the SLC26A4 gene. This protein localizes to the cellular membrane and permits the exchange of anions between the cytosol and extracellular space. In the inner ear, pendrin conditions the endolymph, allowing for the proper function of sensory cells. Understanding the relationship between the genotype and phenotype of pendrin mutations would aid clinicians to better serve PS patients—however, little is known. Here, we summarize the available data concerning SLC26A4 mutations and how they relate to transporter function. The main findings suggest that all the truncation mutations tested annihilate pendrin function, and that the addition or omission of proline, or the addition or omission of charged amino acids in the sequence of SLC26A4 result in a substantial to dramatic reduction in pendrin function.

Journal of Molecular Endocrinology (2009) 43, 93–103

Pendrin function

Pendrin is a member of the anion transporter family SLC26, which mediates, as shown in Fig. 1, the exchange of anions including Cl⁻, HCO₃⁻, OH⁻, I⁻, or formate (Mount & Romero 2004), and is encoded by the SLC26A4 gene. As shown in Fig. 1, in thyrocytes, iodide and sodium are brought into the cells via the basolaterally located sodium–iodide symporter. Apically located pendrin (Royaux et al. 2000) seems to be responsible for the efflux of iodide into the follicular lumen (Yoshida et al. 2002, 2004, Gillam et al. 2004). In the kidney, pendrin is suspected to mediate Cl⁻/HCO₃⁻ exchange in the α- and non-α–β-intercalated cells (Royaux et al. 2001, Soleimani et al. 2001, Kim et al. 2002). A substantial body of work is supporting this concept (Wall 2005, Cantone et al. 2006, Soleimani & Xu 2006, Grimaldi et al. 2007, Hughey & Kleyman 2007, Sindic et al. 2007, Wall & Pech 2008). Similarly, in the inner ear, pendrin is thought to mediate Cl⁻/HCO₃⁻ exchange, and is therefore involved in the conditioning of endolymphatic fluid, presumably due to HCO₃⁻ secretion (Wangemann et al. 2007). Malfunction of pendrin leads to Pendred syndrome (PS).

Pendred syndrome: clinical aspects

PS (OMIM#274600) is an autosomal recessive disorder accounting for 4–10% of inherited hearing losses (Batsakis & Nishiyama 1962, Fraser 1965, Illum et al. 1972, Reardon et al. 1997). It was first described in 1896 as the combination of deafness and goiter (Pendred 1896), but the precise phenotype has been detailed in recent years (Masmoudi et al. 2000, Campbell et al. 2001, Blons et al. 2004, Napiontek et al. 2004) and involves two organ systems: the ear, and the thyroid gland. It is unclear whether or not the kidney could be involved under certain circumstances as well.
SLC26A4 mutations: the ear

Under normal conditions, pendrin maintains the ionic composition of endolymph (Everett et al. 1999). It has therefore been hypothesized that impaired pendrin function i) promotes a progressive increase in endolymph volume followed by an enlargement of the membranous labyrinth and surrounding osseous structures, and ii) leads to degeneration of inner ear sensory cells (Everett et al. 2001). The resulting phenotype is a severe/profound sensorineural hearing loss (SNHL). The onset of deafness fluctuates in about 80% of cases. By contrast, the sudden development of the phenotype occurs only in a minority of patients. SNHL is invariably associated with malformations of the inner ear: enlarged vestibular aqueduct (EVA) is present in all patients with PS (Phelps et al. 1998), whereas Mondini malformations are less common (Yang et al. 2005). These abnormalities can be detected in PS patients by computed tomography or nuclear-magnetic resonance of the petrous part of the temporal bone (Fig. 2).

SLC26A4 mutations: the thyroid

Impaired pendrin function at the thyroid level can result in goiter, defects in iodide organification, and hypothyroidism (Fugazzola et al. 2001, Grimaldi et al. 2007, Kopp et al. 2008). Surprisingly, the thyroid symptoms are highly variable. Indeed, goiter is not a constant feature and can range from a slight increase in thyroid size to a large multinodular goiter. Perchlorate tests have shown that the organification defect is only partial (Fugazzola et al. 2000), indicating the existence of another mechanism underlying the transfer of iodine from the cytoplasm to the colloid (Fig. 1), such as ion channels (Golstein et al. 1992, Yoshida et al. 1999). Accordingly, most patients are euthyroid or subclinical hypothyroid, depending on the level of iodine intake.

SLC26A4 mutations: the kidney

As far as the kidney is concerned, a decrease in pendrin function is not associated with disturbances in renal function. In particular, the regulation of electrolytes and acid–base balance remains normal despite the critical role of pendrin in bicarbonate secretion (Royaux et al. 2001). Indeed, when studied under basal conditions, no renal abnormalities have been reported in either PS patients or Pds-knockout animals. It is assumed that in the kidney, pendrin-dependent ion transport is safeguarded by redundant mechanisms, which most likely attenuate the change in intracellular and systemic pH expected to result from pendrin impairment (Kim et al. 2005). However, differences become apparent under conditions wherein the transporter is stimulated.

Figure 1 Cell model of the ion transport mechanisms in follicular cells of the thyroid gland. The sodium/potassium ATPase and the sodium/iodide symporter (NIS) are located on the basolateral side of follicular cells. At the apical side, pendrin is responsible for iodide transport into the follicles. However, an additional unknown iodide transporter may be expressed in the apical membrane.

Figure 2 Enlarged vestibular aqueduct (EVA) and enlarged endolymphatic sac in PS patients. Computed tomographic (CT)-image (left), and a magnetic resonance image (MRI; right) of the temporal bone of two PS patients with EVA are indicated by an arrow in the CT-image, while the MRI shows an enlarged endolymphatic sac.
Figure 3 Sequence comparison of SLC26A4 in different species. (1) Homo sapiens (NP_000432), (2) Rattus norvegicus (NP_062087), (3) Mus musculus (NP_035997), (4) Pan troglodytes (XP_519308), (5) Macaca mulatta (XP_001094049), (6) Canis familiaris (XP_540382), (7) Bos taurus (XP_608706), (8) Monodelphis domestica (XP_001363598), (9) Gallus gallus (XP_425419), (10) Danio rerio (XP_692273), and (11) Xenopus laevis (NP_001089008). The 15 putative trans-membrane (TM) helices are indicated with arrows and respective numbering (S1–S15). The two amphipathic helices are boxed in red, and the STAS-domain is boxed in blue. The sulfate-transport-consensus-signature is boxed in green, and the glycine repeat is indicated in yellow.
Figure 4 Putative topology of human pendrin. (a) The 12 TM model as described on the Pendred/BOR homepage (http://www.healthcare.uiowa.edu/labs/pendredandbor/domains.htm) using the MEMSAT program. (b) The 15 TM-segment model as proposed in this review. The amino terminus in this model would be located on the extracellular side, and the carboxy terminus would be located at the cytoplasmic side. The 15 trans-membrane (TM) segments are depicted as stretches of amino acids crossing the membrane, which is shown in grey. The position of the TM helices with respect to the membrane (the part of the putative helix that is exposed to the lipid moiety of the membrane) is tentative. The color code of the boxes is equal to that in Fig. 3. It is important to mention that both models are speculative; however, the two models depicted here will help to design experiments, which are needed in order to define the real nature and position of the different TM units.
Following treatment with aldosterone analogs, weight gain, and hypertension are observed in SLC26A4/C but not in SLC26A4/K mice (Wall 2006). Careful studies of renal function after basic and acid loading in PS patients should be performed, and could reveal abnormal handling of anions in the kidney.

No systematic genotype–phenotype correlations have been made so far in PS patients (Lopez-Bigas et al. 1999, Masmoudi et al. 2000, Fugazzola et al. 2007). This review is an attempt to summarize the functional data available as of now for pendrin and its mutants, and to correlate these data to the genotype identified, with the hope that this information will help clinicians to better treat PS patients.

The molecular entity responsible for Pendred syndrome: structural aspects

The clinical patterns described at the level of the thyroid gland and the inner ear are the result of decreases in pendrin function (Everett et al. 1997), a protein encoded by the SLC26A4 gene (NM_000441). There is a high degree of similarity between pendrin in different species. Figure 3 shows the amino acid sequences of pendrin from Homo sapiens, Rattus norvegicus, Mus musculus, Pan troglodytes, Macaca mulatta, Canis familiaris, Bos taurus, Monodelphis domestica, Gallus gallus, Danio rerio, and Xenopus laevis. The respective similarities if compared with the human sequence are 72.5%, with P. troglodytes and M. mulatta being 98.8% similar, and R. norvegicus, M. musculus, C. familiaris, and M. domestica being ≥90% similar (the similarity plot was done by ClustalW; MacVector).

Structural information regarding membrane topology of pendrin is limited and controversial. Whereas Everett et al. (1997) suggest a 11 TM-segment model with the carboxy (C)-terminus at the extracellular site using the PHDhtm program, Royaux et al. (2000) suggest a 12 TM model, with the C-terminus at the cytoplasmatic site. A similar 12 TM model is suggested on the Pendred/BOR homepage (http://www.healthcare.uiowa.edu/labs/pendredandbor/domains.htm) using the MEMSAT program (Zhai & Saier 2001; Fig. 4a). This program, however, predicts an additional 13th TM segment located in the sulfate-transporters-antisigma-factor-antagonist (STAS)-domain of SLC26A4 (Aravind & Koonin 2000), a sequence highly similar to the antisigma-factor-antagonist in bacteria. This sequence is believed to be involved in NTP binding and/or hydrolysis. Aravind & Koonin (2000) postulate that the STAS domain in SLC26-family members could possibly regulate anion-transport by sensing intracellular concentrations of GTP and/or ATP. Furthermore, it was hypothesized that the STAS domain is involved in the interaction of SLC26 members with the cystic-fibrosis-transmembrane-regulator (Ko et al. 2002, 2004); however, the exact function of this domain is still unclear. The 13th TM would bring the C-terminus toward the extracellular site and would therefore be in contrast to the experimental data provided by Gillam.
Table 2 Summary of all functionally characterized allelic variants of SLC26A4

<table>
<thead>
<tr>
<th>Mutation</th>
<th>Pathology</th>
<th>Localization</th>
<th>Function</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td>S28R</td>
<td>PS</td>
<td>PM&lt;sup&gt;a&lt;/sup&gt;</td>
<td>Loss of chloride uptake&lt;sup&gt;b&lt;/sup&gt;</td>
<td>Dossena et al. (2006a,b)</td>
</tr>
<tr>
<td></td>
<td>EVA</td>
<td>Intracellular&lt;sup&gt;d&lt;/sup&gt;</td>
<td>Loss of chloride and iodide transport&lt;sup&gt;c&lt;/sup&gt;</td>
<td>and Yoon et al. (2008)</td>
</tr>
<tr>
<td>E29Q</td>
<td>EVA</td>
<td>Intracellular&lt;sup&gt;d&lt;/sup&gt;</td>
<td>Reduction of Cl&lt;sup&gt;-&lt;/sup&gt;/HCO&lt;sub&gt;3&lt;/sub&gt;&lt;sup&gt;-&lt;/sup&gt; exchange activity&lt;sup&gt;e&lt;/sup&gt;</td>
<td>Pera et al. (2008)</td>
</tr>
<tr>
<td>V88I</td>
<td>EVA (+ R409H)</td>
<td>Intracellular&lt;sup&gt;d&lt;/sup&gt;</td>
<td>Chloride and iodide transport not reduced&lt;sup&gt;c&lt;/sup&gt;</td>
<td>Pera et al. (2008)</td>
</tr>
<tr>
<td>FS93 &gt; 96X&lt;sup&gt;l&lt;/sup&gt; + C416-1G_A&lt;sup&gt;g&lt;/sup&gt;</td>
<td>PS</td>
<td>Intracellular&lt;sup&gt;a,h&lt;/sup&gt;</td>
<td>Intracellular iodine retention (primary thyrocytes)</td>
<td>Palos et al. (2008)</td>
</tr>
<tr>
<td>G102R</td>
<td>PS</td>
<td>ER&lt;sup&gt;i&lt;/sup&gt;</td>
<td>Loss of iodide efflux&lt;sup&gt;k&lt;/sup&gt;</td>
<td>Taylor et al. (2002)</td>
</tr>
<tr>
<td>L117F</td>
<td>EVA</td>
<td>PM&lt;sup&gt;i&lt;/sup&gt;</td>
<td>Iodide efflux equal to wt&lt;sup&gt;k&lt;/sup&gt;</td>
<td>Taylor et al. (2002)</td>
</tr>
<tr>
<td>V138F</td>
<td>PS</td>
<td>ER&lt;sup&gt;i&lt;/sup&gt;</td>
<td>Loss of iodide efflux&lt;sup&gt;k&lt;/sup&gt;</td>
<td>Taylor et al. (2002)</td>
</tr>
<tr>
<td>P140H</td>
<td>EVA</td>
<td>Intracellular&lt;sup&gt;d&lt;/sup&gt;</td>
<td>Loss of chloride and iodide transport&lt;sup&gt;c&lt;/sup&gt;</td>
<td>Yoon et al. (2008)</td>
</tr>
<tr>
<td>P142R</td>
<td>EVA</td>
<td>Intracellular&lt;sup&gt;d&lt;/sup&gt;</td>
<td>Loss of Cl&lt;sup&gt;-&lt;/sup&gt;/HCO&lt;sub&gt;3&lt;/sub&gt;&lt;sup&gt;-&lt;/sup&gt; exchange activity&lt;sup&gt;e&lt;/sup&gt;</td>
<td>Pera et al. (2008)</td>
</tr>
<tr>
<td>M147V</td>
<td>EVA</td>
<td>Intracellular&lt;sup&gt;d&lt;/sup&gt;</td>
<td>Loss of Cl&lt;sup&gt;-&lt;/sup&gt;/HCO&lt;sub&gt;3&lt;/sub&gt;&lt;sup&gt;-&lt;/sup&gt; exchange activity&lt;sup&gt;e&lt;/sup&gt;</td>
<td>Yoon et al. (2008)</td>
</tr>
<tr>
<td>S166N</td>
<td>EVA</td>
<td>PM&lt;sup&gt;d&lt;/sup&gt;</td>
<td>Cl&lt;sup&gt;-&lt;/sup&gt;/HCO&lt;sub&gt;3&lt;/sub&gt;&lt;sup&gt;-&lt;/sup&gt; exchange activity not different from wt&lt;sup&gt;e&lt;/sup&gt;</td>
<td>Yoon et al. (2008)</td>
</tr>
<tr>
<td>G209V</td>
<td>PS, EVA</td>
<td>PM&lt;sup&gt;i&lt;/sup&gt;</td>
<td>Reduction of iodide efflux&lt;sup&gt;x&lt;/sup&gt;</td>
<td>Taylor et al. (2002)</td>
</tr>
<tr>
<td>L236P</td>
<td>PS</td>
<td>ER&lt;sup&gt;i&lt;/sup&gt;</td>
<td>Loss of iodide efflux&lt;sup&gt;k&lt;/sup&gt;</td>
<td>Scott et al. (2000)</td>
</tr>
<tr>
<td></td>
<td>PS</td>
<td>Intracellular&lt;sup&gt;d&lt;/sup&gt;</td>
<td>Loss of chloride and iodide uptake&lt;sup&gt;b,i&lt;/sup&gt;</td>
<td>Taylor et al. (2002)</td>
</tr>
<tr>
<td></td>
<td>PS</td>
<td>Intracellular&lt;sup&gt;d&lt;/sup&gt;</td>
<td>Loss of chloride efflux&lt;sup&gt;x&lt;/sup&gt;</td>
<td>Rotman-Pikielny et al. (2002)</td>
</tr>
<tr>
<td>FS297 &gt; 302X</td>
<td>PS, EVA</td>
<td>PM&lt;sup&gt;i&lt;/sup&gt;</td>
<td>Reduction of iodide efflux&lt;sup&gt;k&lt;/sup&gt;</td>
<td>Yoon et al. (2008)</td>
</tr>
<tr>
<td>F335L</td>
<td>EVA</td>
<td>PM&lt;sup&gt;i&lt;/sup&gt;</td>
<td>Reduction of Cl&lt;sup&gt;-&lt;/sup&gt;/I&lt;sup&gt;-&lt;/sup&gt; and Cl&lt;sup&gt;-&lt;/sup&gt;/HCO&lt;sub&gt;3&lt;/sub&gt;&lt;sup&gt;-&lt;/sup&gt; exchange activity&lt;sup&gt;y&lt;/sup&gt;</td>
<td>Choi et al. (2008)</td>
</tr>
<tr>
<td>FS306 &gt; 309X</td>
<td>PS</td>
<td>Intracellular&lt;sup&gt;i&lt;/sup&gt;</td>
<td>Loss of chloride efflux&lt;sup&gt;k&lt;/sup&gt;</td>
<td>Gillam et al. (2004)</td>
</tr>
<tr>
<td>E384G</td>
<td>PS</td>
<td>ER&lt;sup&gt;i&lt;/sup&gt;</td>
<td>Loss of chloride and iodide uptake&lt;sup&gt;b,i&lt;/sup&gt;</td>
<td>Scott et al. (2000)</td>
</tr>
<tr>
<td></td>
<td>PS</td>
<td>Intracellular&lt;sup&gt;d&lt;/sup&gt;</td>
<td>Loss of Cl&lt;sup&gt;-&lt;/sup&gt;/HCO&lt;sub&gt;3&lt;/sub&gt;&lt;sup&gt;-&lt;/sup&gt; exchange activity&lt;sup&gt;e&lt;/sup&gt;</td>
<td>Choi et al. (2008)</td>
</tr>
<tr>
<td></td>
<td>PS</td>
<td>Intracellular&lt;sup&gt;d&lt;/sup&gt;</td>
<td>Loss of Cl&lt;sup&gt;-&lt;/sup&gt;/I&lt;sup&gt;-&lt;/sup&gt; exchange activity&lt;sup&gt;y&lt;/sup&gt;</td>
<td>Yoon et al. (2008)</td>
</tr>
<tr>
<td></td>
<td>EVA</td>
<td>Partially PM&lt;sup&gt;a&lt;/sup&gt;</td>
<td>Loss of iodide efflux&lt;sup&gt;k&lt;/sup&gt;</td>
<td>Gillam et al. (2005)</td>
</tr>
<tr>
<td></td>
<td>EVA</td>
<td>Intracellular&lt;sup&gt;d&lt;/sup&gt;</td>
<td>Loss of chloride and iodide transport&lt;sup&gt;c&lt;/sup&gt;</td>
<td>Dossena S &amp; Paulmichl M (personal communication)</td>
</tr>
<tr>
<td></td>
<td>EVA</td>
<td>Intracellular&lt;sup&gt;d&lt;/sup&gt;</td>
<td>Loss of iodide efflux&lt;sup&gt;k&lt;/sup&gt;</td>
<td>Yoon et al. (2008)</td>
</tr>
<tr>
<td></td>
<td>EVA</td>
<td>Intracellular&lt;sup&gt;d&lt;/sup&gt;</td>
<td>Reduction of iodide and chloride transport&lt;sup&gt;c&lt;/sup&gt;</td>
<td>Gillam et al. (2005)</td>
</tr>
<tr>
<td></td>
<td>EVA</td>
<td>Intracellular&lt;sup&gt;d&lt;/sup&gt;</td>
<td>Loss of iodide efflux&lt;sup&gt;k&lt;/sup&gt;</td>
<td>Palos et al. (2008)</td>
</tr>
<tr>
<td></td>
<td>EVA</td>
<td>Intracellular&lt;sup&gt;d&lt;/sup&gt;</td>
<td>Reduction of iodide and chloride transport&lt;sup&gt;c&lt;/sup&gt;</td>
<td>(personal communication)</td>
</tr>
<tr>
<td></td>
<td>EWA</td>
<td>Intracellular&lt;sup&gt;d&lt;/sup&gt;</td>
<td>Loss of iodide efflux&lt;sup&gt;k&lt;/sup&gt;</td>
<td>Yoon et al. (2008)</td>
</tr>
<tr>
<td></td>
<td>EVA</td>
<td>Intracellular&lt;sup&gt;d&lt;/sup&gt;</td>
<td>Reduction of the chloride and iodide transport&lt;sup&gt;c&lt;/sup&gt;</td>
<td>Choi et al. (2008)</td>
</tr>
<tr>
<td></td>
<td>EVA</td>
<td>Intracellular&lt;sup&gt;d&lt;/sup&gt;</td>
<td>Reduction of chloride and iodide transport&lt;sup&gt;c&lt;/sup&gt;</td>
<td>Choi et al. (2008)</td>
</tr>
<tr>
<td></td>
<td>EVA</td>
<td>Intracellular&lt;sup&gt;d&lt;/sup&gt;</td>
<td>Reduction of chloride and iodide transport&lt;sup&gt;c&lt;/sup&gt;</td>
<td>Yoon et al. (2008)</td>
</tr>
<tr>
<td></td>
<td>EVA</td>
<td>Intracellular&lt;sup&gt;d&lt;/sup&gt;</td>
<td>Mild reduction of chloride and iodide uptake&lt;sup&gt;b,i&lt;/sup&gt;</td>
<td>Scott et al. (2000)</td>
</tr>
<tr>
<td></td>
<td>EVA</td>
<td>Intracellular&lt;sup&gt;d&lt;/sup&gt;</td>
<td>Strong reduction of chloride and iodide uptake&lt;sup&gt;b,i&lt;/sup&gt;</td>
<td>Yoon et al. (2008)</td>
</tr>
<tr>
<td></td>
<td>EVA</td>
<td>Intracellular&lt;sup&gt;d&lt;/sup&gt;</td>
<td>Loss of chloride and iodide uptake&lt;sup&gt;b,i&lt;/sup&gt;</td>
<td>Scott et al. (2000)</td>
</tr>
<tr>
<td></td>
<td>EVA</td>
<td>Intracellular&lt;sup&gt;d&lt;/sup&gt;</td>
<td>Reduction of chloride and iodide uptake&lt;sup&gt;b,i&lt;/sup&gt;</td>
<td>Scott et al. (2000)</td>
</tr>
</tbody>
</table>

(continued)
et al. (2004), and therefore it was probably ignored in the 12 TM model using the MEMSAT program. Here, we show another putative model of SLC26A4, using the MEMSAT prediction as a starting point and after refining the model according Sweet & Eisenberg (1983), and Shafrir & Guy (2004). In this model, SLC26A4 would be formed by up to 15 TM helical segments (Table 1 and Fig. 4b). The TM segments marked amphipathic are the most ambiguous in terms of their localization, which could be transmembrane, cytosolic, or extracellular. However, since the sequence homology of these segments between the different species is very high (Fig. 3), it could be assumed that these segments could indeed form TM helices as opposed to helices located on either surface of the membrane. However, more rigorous experiments are needed to distinguish between the different possibilities. By assuming that the C-terminus is located within the cytosol, the amino terminus would have to be located on the extracellular side in both the 15 TM and 13 TM (minus the two amphipathic helices) models. This is in direct contrast to the model suggested by Gillam, in which the amino terminus is located within the cytosol (Gillam et al. 2004). Again, all the SLC26A4 models proposed so far, including our model proposed here, are speculative and lack experimental evidence; therefore, more rigorous experiments are necessary to unambiguously determine the secondary and tertiary structure of SLC26A4. The third TM segment in Fig. 4b harbors the sulfate-transport-consensus-signature (Mount & Romero 2004), a stretch of amino acids involved in the transport of sulfate in SLC26A1, A2, A3, A6-9, and A11 (Mount & Romero 2004). This sequence is, however, modified in SLC26A4, which is consistent with the data showing that pendrin does not transport sulfate (Scott et al. 1999, Bogazzi et al. 2000, Scott & Karniski 2000). An additional structural aspect of pendrin, as shown in Figs 3 and 4b, is the presence of glycines at every fourth position in the putative TM segment 15 (boxed in yellow in Figs 3 and 4b). It is possible that the arrangement of these amino acids may play a role in the homodimerization of the protein. The product of a wild-type allele could be functionally hampered if dimerized with the product of a mutated allele. This is of particular significance when considering the discussion by Scott et al. (2000), which describes that the combination of certain SLC26A4 mutations could be dominant negative.

**Genetics of Pendred syndrome**

Presently, more than 140 mutations in the SLC26A4 gene have been described (www.healthcare.uiowa.edu/labs/pendredandbor) in PS and EVA, which have been detected within the coding sequence, splice sites, non-coding exon 1, and within the FOXI1 binding transcriptional regulatory elements (Yang et al. 2007). Approximately 62% of all mutations are missense changes, most of which have been described in single families.
Functional characterization of pendrin

As described earlier, pendrin is involved in anion transport within the ear, thyroid, and kidney. It was shown that human pendrin expressed in monkey cells leads to chloride currents (Yoshida et al. 2002). However, we showed that human pendrin expressed in human cells does not lead to the activation of chloride currents, but by contrast leads to an increase in cationic currents. The latter experiments suggest that SLC26A4 induced chloride transport is per se electro-neutral when expressed in human cellular systems (for more details, see Dossena et al. (2005)). Since the exact coupling ratio and hence rheogeneity of pendrin is still in debate, it would be desirable to investigate the electrical behavior of SLC26A4 expressed in a polarized epithelium, since the electrophysiological studies performed so far in non-polarized cells might not reflect the physiological 'context' of SLC26A4 function. The only study in which Pendrin function was investigated in a polarized epithelium was published by Gillam et al. (2004), in which they assessed the basolateral to apical flux of radioactive iodide.

The authors hypothesized in their study that the SLC26A4-mediated transport could be electroneutral or mediated via channels, which would imply rheogenic transport. We also used a radioactive-flux technique to characterize wild-type and mutant SLC26A4 functions (Dossena et al. 2006b) and from these and the results mentioned above, we can conclude that the SLC26A4-mediated transport is electroneutral.

Can pendrin function be predicted by genotype?

The two criteria used so far for assuming pathogenicity of SLC26A4 gene mutations are i) low incidence of the mutation in the control population and ii) substitution of evolutionary conserved amino acids. However, we recently showed that these criteria are not reliable parameters for predicting SLC26A4 function (Pera et al. 2008). In Table 2, we have summarized all the SLC26A4 mutations for which functional data are available at the moment. The tests used for determining SLC26A4 transporter functionality range from...
radioactive flux studies and localization in cells to assays utilizing intracellular fluorescent indicators to sense changes in halide and/or proton amounts (Table 2; it is important to note that the concentration of iodide in the different tests changes from very low (radioactive flux studies) to very high (fluorometric method)). The different techniques are consistent with each other and showed that entire proteins, not just the presumed transmembrane elements, are crucial for proper function. As shown in Fig. 5, deleterious mutations have been detected from amino acid 28 through amino acid 724 out of the 780 residue-long pendrin transporter. The hypothesis that the entire protein seems to be important is further substantiated in that all mutations leading to truncations are functionally inactive (Fig. 5). It is difficult at the moment to unambiguously link the severity of hearing loss (moderate, severe, and profound) to individual SLC26A4 mutations. Mutations with no transport activity (P140H, Q413P, Q514K, and D724G) and with reduced activity (E29Q, V881/R409H, G424D, and T485R) are equally identified in patients with PS and ns-EVA suffering from moderate to profound hearing loss (Taylor et al. 2002, Pera et al. 2008a). The simplest explanation for the difficulty in correlating a specific SLC26A4 mutation to clinical symptoms is that additional genetic-, epigenetic-, and/or environmental factors could substantially modify the observed disease phenotype (Pera et al. 2008a). This is further corroborated in that SLC26A4 zero mutants can show EVA and severe hearing loss, and patients with mono-allelic SLC26A4 mutations can show severe to profound hearing loss without EVA (Pera et al. 2008a). Accordingly, Pryor et al. (2005) found that at least some cases of non-syndromic EVA are associated with a single SLC26A4 mutation, whereas PS is a genetically homogeneous disorder caused by biallelic SLC26A4 mutations. It should be noted that patients thought to have a monoallelic mutation may have an undetected mutation in a regulatory or intronic region (Gillam et al. 2005, Pryor et al. 2005). Despite the fact that it is difficult at the moment to correlate genotype (SLC26A4) and phenotype (moderate to profound hearing loss), it is noteworthy to mention that a patient homozygous for the Q514K mutation (loss-of-function) showed bilateral, sensorineural, and profound deafness at the age of 2, whereas a separate patient, we described, carrying two mutations with only reduced transport activity (E29Q and V881/R409H), had sensorineural, moderate/mild hearing loss at the age of 44 (Pera et al. 2008a). These data indicate that the functional tests could indeed help explain the severity of particular pendrin mutations.

Our former work (Pera et al. 2008a) suggested that certain biochemical parameters could explain some functional impairments. For example, in all mutations depicted in Fig. 5, an impairment in transport function was found if an amino acid bearing a fixed charge (aspartic acid (D\(^-\)) or glutamic acid (E\(^-\)), lysine (K\(^+\)) or arginine (R\(^+\)), and histidine (H\(^+\)) single letter code, and the sign indicates the fixed charge; the positive charge of histidine depends on the pH) was missing or introduced. Furthermore, the loss or inclusion of a proline (P; proline acts as a structural disruptor of regular secondary structures such as \(\alpha\)-helices or \(\beta\)-sheets) in the SLC26A4 sequence is detrimental for transport function. However, Pfarr et al. (2006) described one exception, in which an allelic variant (R776C; Fig. 5) functioned like the controls. Interestingly, this particular arginine is located on the extreme C-terminus of SLC26A4 (a 780 amino acid protein). The N- and C-termini of a protein are usually not structurally defined; therefore, it is plausible to assume that mutations occurring in these areas probably have little or no functional impact.

It is important to note that mutations which do not enter into this ‘proline/fixed charge’ role can be functionally detrimental or without functional implication (Scott et al. 2000, Taylor et al. 2002, Gillam et al. 2004, Pfarr et al. 2006, Fugazzola et al. 2007). In Fig. 5, this applies for 12 out of the 36 mutations for which a functional reduction was described. In these roughly 33% of the cases, only functional tests can unambiguously distinguish between SLC26A4 single-nucleotide-polymorphisms and those mutations that actually cause a reduced function and ultimately signs of disease.

In conclusion, it has become apparent that the two parameters used so far, i.e. i) low incidence of the mutation in the control population and ii) substitution of evolutionary conserved amino acids by the mutation, are not reliable for predicting SLC26A4 transport function. The findings summarized here reveal that the ‘proline/fixed charge’ role, i.e. the addition or omission of proline, or the addition or omission of charged amino acids in the sequence of SLC26A4, might be a better option for predicting SLC26A4 function in the cases where direct functional tests cannot be performed.

**Declaration of interest**

The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research reported.

**Funding**

This work was supported by the Italian Ministry of Instruction, University and Research (MIUR, prot 2003060317), the Austrian Science Fund (FWF: P18608-B05), and the PMU research fund.
Acknowledgements

We would like to thank Seth Alper (Harvard) and Andy Griffith (NIH) for sharing their manuscripts prior to publication. We thank H Robert Guy for assistance in analyzing the sequence and for comment about the manuscript. Charity Noziger is supported be the Lise Meitner stipend of the FWF (M1108-B11).

This work is dedicated to Helga and Erich Kellerhals.

References


Everett LA, Morsli H, Wu DK & Green ED 1999 Expression pattern of the mouse ortholog of the Pendred’s syndrome gene (Pds) suggests a key role for pendrin in the inner ear. PNAS 96 9727–9732.


Wall SM 2005 Recent advances in our understanding of intercalated cells. *Current Opinion in Nephrology and Hypertension* 14:480–484.


